Last update 12 May 2026

SNH-119014

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms
SNH-119014
Target
Pyruvate kinases
Action
stimulants
Mechanism
Pyruvate kinases stimulants
Therapeutic Areas
Congenital DisordersHemic and Lymphatic DiseasesOther Diseases
Active Indication
Non-transfusion dependent thalassaemiaAnemia, Sickle CellBeta-Thalassemia
Inactive Indication-
Originator Organization
ScinnoHub Pharmaceutical Co., Ltd.ScinnoHub Pharmaceutical Co., Ltd.
Active Organization
Brilliant Pharmaceutical Co. Ltd.Brilliant Pharmaceutical Co. Ltd.ScinnoHub Pharmaceutical Co., Ltd.ScinnoHub Pharmaceutical Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with SNH-119014
NCT07579949
/ Not yet recruitingPhase 2
A Phase 2 Study to Determine the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SNH-119014 in Adult Subjects With Non-transfusion-dependent Thalassemia
NCT07087262
/ RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic of SNH-119014 in Healthy Adult Volunteers
CTR20261588
/ Not yet recruitingPhase 2
SNH-119014片治疗地中海贫血患者的安全性、有效性及药代动力学/药效学的IIa期研究
[Translation] A Phase IIa study of the safety, efficacy, and pharmacokinetic/pharmacodynamic properties of SNH-119014 tablets in the treatment of thalassemia patients.
100 Clinical Results associated with SNH-119014
Login to view more data
100 Translational Medicine associated with SNH-119014
Login to view more data
100 Patents (Medical) associated with SNH-119014
Login to view more data
100 Deals associated with SNH-119014
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-transfusion dependent thalassaemiaPhase 2
China
ScinnoHub Pharmaceutical Co., Ltd.ScinnoHub Pharmaceutical Co., Ltd.
18 Jun 2026
Anemia, Sickle CellPhase 2
China
Brilliant Pharmaceutical Co. Ltd.Brilliant Pharmaceutical Co. Ltd.
23 Apr 2026
Beta-ThalassemiaPhase 2
China
Brilliant Pharmaceutical Co. Ltd.Brilliant Pharmaceutical Co. Ltd.
23 Apr 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free